Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Changes in synaptic proteins precede neurodegeneration markers in preclinical Alzheimer's disease cerebrospinal fluid

  • Lleó, Alberto|||0000-0002-2568-5478
  • Núñez-Llaves, Raúl|||0000-0002-6702-4774
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Chiva, Cristina
  • Balateu Paños, Daniel
  • Colom-Cadena, Martí|||0000-0002-8514-4534
  • Gómez, Gemma
  • Muñoz, Laia|||0000-0003-0578-3094
  • Querol-Vilaseca, Marta|||0000-0002-8589-1636
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Rami Gonzalez, Lorena|||0000-0002-7411-1921
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
  • Molinuevo, José Luis|||0000-0003-0485-6001
  • Tainta, Mikel|||0000-0003-0624-1211
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Spires Jones, Tara
  • Blesa, Rafael|||0000-0003-4026-2884
  • Fortea, Juan|||0000-0002-1340-638X
  • Martínez Lage, Pablo
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Sabidó, Eduard|||0000-0001-6506-7714
  • Bayés, Àlex|||0000-0002-5265-6306
  • Belbin, Olivia|||0000-0002-6109-6371
A biomarker of synapse loss, an early event in Alzheimer's disease (AD) pathophysiology that precedes neuronal death and symptom onset, would be a much-needed prognostic biomarker. With direct access to the brain interstitial fluid, the cerebrospinal fluid (CSF) is a potential source of synapse-derived proteins. In this study, we aimed to identify and validate novel CSF biomarkers of synapse loss in AD. Discovery: Combining shotgun proteomics of the CSF with an exhaustive search of the literature and public databases, we identified 251 synaptic proteins, from which we selected 22 for further study. Verification: Twelve proteins were discarded because of poor detection by Selected Reaction Monitoring (SRM). We confirmed the specific expression of 9 of the remaining proteins (Calsyntenin-1, GluR2, GluR4, Neurexin-2A, Neurexin-3A, Neuroligin-2, Syntaxin-1B, Thy-1, Vamp-2) at the human synapse using Array Tomography microscopy and biochemical fractionation methods. Exploration: Using SRM, we monitored these 9 synaptic proteins (20 peptides) in a cohort of CSF from cognitively normal controls and subjects in the pre-clinical and clinical AD stages (n 80). Compared with controls, peptides from 8 proteins were elevated 1.3 to 1.6-fold (p < 0.04) in prodromal AD patients. Validation: Elevated levels of a GluR4 peptide at the prodromal stage were replicated (1.3-fold, p 0.04) in an independent cohort (n 60). Moreover, 7 proteins were reduced at preclinical stage 1 (0.6 to 0.8-fold, p < 0.04), a finding that was replicated (0.7 to 0.8-fold, p < 0.05) for 6 proteins in a third cohort (n 38). In a cross-cohort meta-analysis, 6 synaptic proteins (Calsyn-tenin-1, GluR4, Neurexin-2A, Neurexin-3A, Syntaxin-1B and Thy-1) were reduced 0.8-fold (p < 0.05) in preclinical AD, changes that precede clinical symptoms and CSF markers of neurodegeneration. Therefore, these proteins could have clinical value for assessing disease progression, especially in preclinical stages of AD.